浙江医药：10月27日召开董事会会议

Core Viewpoint - Zhejiang Medicine announced a board meeting to discuss the 2025 restricted stock incentive plan, indicating a strategic move to enhance employee motivation and align interests with shareholders [1] Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition was as follows: pharmaceuticals accounted for 51.44%, human nutritional products for 47.06%, other products for 0.85%, and other business activities for 0.66% [1] Market Position - As of the report, Zhejiang Medicine's market capitalization stood at 13.9 billion yuan [1]